Mosaic Therapeutics in-licenses Two Clinical-stage Oncology Programs From Astex Pharmaceuticals for Development as Proprietary Combination Therapies
- In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business
- Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential of the assets
- As part of the agreement Astex has taken an equity stake in Mosaic